Pharmaceutical News

RSS

Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Wound Management Technologies, Inc. announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® . In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.

26 Feb 2010

Vion Pharmaceuticals' Onrigin SPA: FDA responds

VION PHARMACEUTICALS, INC. announced today that it had received a response from the U.S. Food and Drug Administration on a Special Protocol Assessment for its oncology therapeutic Onrigin™ (laromustine) Injection.

26 Feb 2010

Arena Pharmaceuticals' lorcaserin NDA: FDA assigns PDUFA date

Arena Pharmaceuticals, Inc. announced today that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of October 22, 2010, for the review of the lorcaserin New Drug Application (NDA). The acceptance of the lorcaserin NDA filing confirms that the application is sufficiently complete to permit a substantive review, and the PDUFA date is the goal date for the FDA to complete its review of the NDA.

26 Feb 2010

Prevention of heart attacks: Resveratrol appears to exhibit broader action than aspirin

With the realization that half of the people experiencing a sudden mortal heart attack were taking aspirin on the day of their demise, and the fact that higher-than-recommended doses of aspirin are needed to prevent blood clot formation in coronary arteries, coupled with an announcement that the red wine molecule resveratrol (rez-vair-ah-trawl) may protect from sudden mortal heart attack in a superior fashion to aspirin, suggests re-evaluation of cardiology's current instruction regarding prevention of heart attacks, says Nate Lebowitz MD, cardiologist with the Advanced Cardiology Institute in Ft. Lee, New Jersey.

26 Feb 2010

Possible damage to children caused by compulsory vaccines: CVS calls for investigation of federal agencies

In a letter to the Chairmen and Ranking Members of House and Senate Committees charged with oversight of the Department of Health and Human Services (HHS), the Coalition for Vaccine Safety (CVS) is calling for hearings to investigate HHS, the Centers for Disease Control (CDC) and other government agencies for failure to fully address issues of vaccine safety as intended by the Mandate for Safer Vaccines in the 1986 National Childhood Vaccine Injury Compensation Act.

26 Feb 2010

Rapid, multiplexed genotyping method to identify SNPs that affect warfarin dose developed

Researchers from the Ohio State University have developed a rapid, multiplexed genotyping method to identify the single nucleotide polymorphisms (SNPs) that affect warfarin dose. The related report by Yang et al, "Rapid Genotyping of SNPs Influencing Warfarin Drug Response by SELDI-TOF Mass Spectrometry," appears in the March 2010 issue of the Journal of Molecular Diagnostics.

26 Feb 2010

Go4Europe conference to focus on current situation of pharmaceutical companies

The 8th Go4Europe conference, held on March 15, 2010 in the Tel Aviv Hilton, will include a panel focusing on "Innovation for Pharma and Access to Finance for Biotech."

26 Feb 2010

Study identifies risk factors for vitamin D deficiency in kidney disease patients on dialysis

Vitamin D deficiency is almost universal among kidney disease patients who have low blood protein levels and who start dialysis during the winter, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The research identifies a group of patients who are at extremely high risk of being deficient in vitamin D and provides some clues as to why the deficiency occurs in these individuals.

26 Feb 2010

New dietary supplement blocks triggering mechanism causing breast cell mutations

Every 13 minutes a woman loses her battle with breast cancer and in 2009 alone more than 27,000 men died from prostate cancer. These powerful statistics continue to fuel research and new developments. With tens of millions of dollars in financial support from the National Cancer Institute and the U.S. Department of Defense, scientists have identified when estrogen metabolism is out of balance it can start the process leading to breast cell mutations.

26 Feb 2010

USPTO issues notice of allowance for Vanda Pharmaceuticals' Fanapt long-acting injectable formulation

Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.

26 Feb 2010

Scientists identify new way to treat castrate resistant cells in prostate cancer patients

Monash University biomedical scientists have identified a new way to treat castrate resistant cells in prostate cancer sufferers - the most common cancer in Australian men.

25 Feb 2010

E. Fougera receives first generic approval for Imiquimod Cream 5%

E. Fougera & Co., a leading specialty pharmaceutical manufacturer, today announced it has received first generic approval from the FDA for Imiquimod Cream 5% (Rx). Fougera's Imiquimod Cream 5% is rated AB, generically equivalent to Aldara® by Graceway Pharmaceuticals and substitutable for all indications. According to industry data, U.S. sales of the brand named product in 2009 exceed $360 million.

25 Feb 2010

FDA sets new PDUFA action date for exenatide once weekly NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) has set a new Prescription Drug User Fee Act (PDUFA) action date of March 12 for its review of the exenatide once weekly new drug application (NDA).

25 Feb 2010

Sales revenue from Labopharm's once-daily tramadol increases to $4.7M for fourth-quarter fiscal 2009

Labopharm Inc. today reported its financial results for the fourth quarter and fiscal year ended December 31, 2009. All figures are in Canadian dollars unless otherwise stated.

25 Feb 2010

Dangers of steroid abuse: Steroids.com gone live

Effective today, Steroids.com has gone live under new ownership with the primary goal to educate youths about the dangers of steroid abuse. Backed by the legal team at Womack & Associates of Houston, Texas, Steroids.com aims to become the de-facto informational website related to all things steroids.

25 Feb 2010

Texas Plant-Expressed Vaccine Consortium announces biotherapeutic manufacturing initiative for infectious diseases

Leaders of the Texas Plant-Expressed Vaccine Consortium today announced a biotherapeutic manufacturing initiative designed to show proof of concept for a landmark new technology that could dramatically increase the nation's capability to produce vaccines for infectious diseases, including influenza.

25 Feb 2010

FEHBP's H.R. 4489 overhaul will undermine cost-saving tools and disrupt prescription drug benefits

“Regrettably, the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (H.R. 4489) would undermine many of the cost-saving tools used in FEHBP and disrupt prescription drug benefits for 8 million federal employees, retirees, and their families.”

25 Feb 2010

Myeloma Canada calls on Quebec government to approve Revlimid as second-line therapy

The Government of Quebec's Ministère de la santé et des services sociaux has approved the addition of Revlimid(R) (lenalidomide) to the Province's Drug Formulary as a third-line therapy for multiple myeloma patients. The cost of the drug will be reimbursed under the Province's medicare system.

25 Feb 2010

Texas-based consortium announces biotherapeutic manufacturing initiative for vaccine production

25 Feb 2010

Signaling molecules may link certain actions of B cells to solid tumor growth: Study

Cancer researchers studying the immune system have identified a previously unrecognized set of targets and biomarkers to battle solid tumors.

25 Feb 2010

Pharmaceutical News

Wound Management Technologies announces recent increase in sales of CellerateRx throughout U.S.

Vion Pharmaceuticals' Onrigin SPA: FDA responds

Arena Pharmaceuticals' lorcaserin NDA: FDA assigns PDUFA date

Prevention of heart attacks: Resveratrol appears to exhibit broader action than aspirin

Possible damage to children caused by compulsory vaccines: CVS calls for investigation of federal agencies

Rapid, multiplexed genotyping method to identify SNPs that affect warfarin dose developed

Go4Europe conference to focus on current situation of pharmaceutical companies

Study identifies risk factors for vitamin D deficiency in kidney disease patients on dialysis

New dietary supplement blocks triggering mechanism causing breast cell mutations

USPTO issues notice of allowance for Vanda Pharmaceuticals' Fanapt long-acting injectable formulation

Scientists identify new way to treat castrate resistant cells in prostate cancer patients

E. Fougera receives first generic approval for Imiquimod Cream 5%

FDA sets new PDUFA action date for exenatide once weekly NDA

Sales revenue from Labopharm's once-daily tramadol increases to $4.7M for fourth-quarter fiscal 2009

Dangers of steroid abuse: Steroids.com gone live

Texas Plant-Expressed Vaccine Consortium announces biotherapeutic manufacturing initiative for infectious diseases

FEHBP's H.R. 4489 overhaul will undermine cost-saving tools and disrupt prescription drug benefits

Myeloma Canada calls on Quebec government to approve Revlimid as second-line therapy

Texas-based consortium announces biotherapeutic manufacturing initiative for vaccine production

Signaling molecules may link certain actions of B cells to solid tumor growth: Study

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News